A Randomized, Blinded, Parallel-Group, Phase 1 Study of Pharmacokinetics, Safety and Tolerability of Single Intravenous Doses of BIIB033 (Opicinumab ) Produced by 2 Manufacturing Processes, in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2016
At a glance
- Drugs Opicinumab (Primary)
- Indications Multiple sclerosis; Optic neuritis
- Focus Pharmacokinetics
- Sponsors Biogen
- 06 Dec 2016 Status changed from active, no longer recruiting to completed.
- 07 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 18 Aug 2016 Status changed from not yet recruiting to recruiting.